Lymphokine activated killers (which includes NK cells) from patients receiving IL-2 infusion, in combination with mouse or chimeric anti-GD2 antibody therapy, increased ADCC against neuroblastoma target cells, providing rationale for administering IL-2 in vivo to boost antitumor response [134]. Here, IL2 is linked to neuroblastoma.